Comparison of 123I‐metaiodobenzylguanidine (MIBG) and 131I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group

Authors:

Abstract
Background 123I‐metaiodobenzylguanidine (MIBG) scans are preferable to 131I‐MIBG for neuroblastoma imaging as they deliver less patient radiation yet have greater sensitivity in disease detection. Both 123I‐MIBG and 131I‐MIBG scans were used for disease assessments of neuroblastoma patients enrolled on Children's Oncology Group (COG) high‐risk study A3973. The hypothesis was that 123I‐MIBG and 131I‐MIBG scans were sufficiently similar for clinical purposes in terms of ability to predict survival. Procedure Patients enrolled on COG A3973 with stage 4 disease who completed 123I‐MIBG or 131I‐MIBG scans at diagnosis, post‐induction, post‐transplant, or post‐biotherapy were analyzed. The performance of the Curie score for each MIBG scan type in predicting survival was evaluated. At each time point, survival curves for 123I‐MIBG versus 131I‐MIBG were compared using the log‐rank test. Results Of the 413 patients on A3973 with at least one MIBG scan, 350 were stage 4. The 5‐year event‐free survival (EFS) and overall survival (OS) rates were 33.4 ± 3.6% and 45.6 ± 4.0% (N = 350). At post‐induction, EFS (P = 0.3501) and OS (P = 0.5337) for 123I‐MIBG versus 131I‐MIBG were not significantly different. Similarly, comparisons at the three other time points were non‐significant. Conclusions We found no evidence of a statistically significant difference in outcome by type of scan. For future survival analyses of MIBG Curie scores, 123I‐MIBG and 131I‐MIBG results may be combined and analyzed overall, without adjustment for scan type. Pediatr Blood Cancer 2011;56:1041–1045.
Funding Information
  • Children's Oncology Group (U10 CA98413, U10 CA98543)

This publication has 34 references indexed in Scilit: